TABLE 2.
The Follow-up of the Cohort and Oncological Status in October 2021 of the 62 Pediatric Patients Undergoing Cancer Treatment with Detectable SARS-CoV-2 by RT-PCR, Between March 1, 2020 and November 30, 2021, and the Distribution of the 18 Deaths During the Study Period by Type of Cancer, Stage of Cancer Treatment and Survival Time Between the Diagnosis of Cancer and COVID-19 and Death
| Variables | Absolute Frequency n | Relative Frequency % |
|---|---|---|
| All patients—status at the end of the study (follow-up 18 months) | n = 62 | % |
| Undergoing treatment | 20 | (32.3) |
| Complete remission | 20 | (32.3) |
| Recurrence/palliative care | 4 | (6.4) |
| Death | 18 | (29.0) |
| Patients who died before the end of the study | n = 18 | % |
| Type of cancer | ||
| Leukemias | 7 | (38.9) |
| Lymphomas | – | – |
| Solid tumors | 11 | (61.1) |
| Neuroblastoma | 3 | (16.6) |
| CNS tumor | 3 | (16.6) |
| Sarcomas and others | 5 | (27.8) |
| Phase of oncological treatment | ||
| Induction/consolidation | 13 | (72.2) |
| Maintenance/reinduction | 3 | (16.7) |
| Palliative care | 2 | (11.1) |
| Time between diagnosis of COVID-19 and death | ||
| Extreme (days and months) | 1 day to 13 months | |
| Mean (±SD) days | 215 (±155) | |
| Median (interquartile interval) days | 171 (99–320) | |
| Time between diagnosis of cancer and death | ||
| Extreme (days and months) | 20 days to 76 months | |
| Mean (±SD) days | 241 (±525) | |
| Median (interquartile interval) days | 275 (124–499) |
COVID-19 indicates coronavirus disease 2019.